But the diagnosis is made on the basis of a spectrum of clinical manifestations such as impaired regulation of hepatic glucose production, incremental decline in β-cell function, destruction of pancreatic β-cells in a small subset of type 2 diabetic patients, insulin resistance (also known as impaired insulin sensitivity), genetic mutations, dyslipidemia, or hormonal diseases. This evidence concerns the gene INS and metabolic syndrome.